Chris Tackaberry, founder and CEO of Clinithink, reviews the role of AI in transforming the diagnostic odyssey, focusing on RCIGM’s work with Clinical Natural Language Processing.
Menu
Home / About Us / News Center / Media Coverage / How AI is Transforming Rare Disease Diagnosis
Chris Tackaberry, founder and CEO of Clinithink, reviews the role of AI in transforming the diagnostic odyssey, focusing on RCIGM’s work with Clinical Natural Language Processing.
© 2024 Rady Children's Institute for Genomic Medicine.